In short: Named only as the competitor — "a rival drug from Arvinas has already won approval in this same indication and now holds the lead position," which makes AZN's camizestrant Phase 3 failure in hormone-driven metastatic breast cancer "sting slightly more." No view on Arvinas shares.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.